Skip to content
Politically.com Search all
Menu

2025 · 3rd Quarter (July 1 - Sep 30)

TEVA PHARMACEUTICALS USA, INC.

Filed by FAEGRE DRINKER BIDDLE & REATH LLP.

Open official filing
Source: Lobbying Disclosure APIRecently refreshed. 2026-08-03 06:26:15 UTC.

Source-reported fields

Filing overview

Type
3rd Quarter - Report
Posted
Oct 17, 2025
Income
$60,000.00
Expenses
Not reported
Filing UUID
42999aa6-29ea-450d-bd5c-7cc027a15fbe
Termination date
Not reported

Literal source text

Lobbying issues and bill citations

HCR · Health Issues

Skinny Labels, Big Savings Act (S 43). Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals (S 1096, HR 1843). Implementation of Inflation Reduction Act pricing proposal. Oversight and reform efforts affecting pharmacy benefit managers. Patent reform (S 1095, S 1097). Proposals related to drug shortages. Proposals related to pharmaceutical tariffs; Proposals related to drug pricing reform.

Literal federal measure citations: S 43, S 1096, HR 1843, S 1095, S 1097

CPT · Copyright/Patent/Trademark

Skinny Labels, Big Savings Act (S 43). Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals (S 1096, HR 1843). Implementation of Inflation Reduction Act pricing proposal. Oversight and reform efforts affecting pharmacy benefit managers. Patent reform (S 1095, S 1097). Proposals related to drug shortages. Proposals related to pharmaceutical tariffs; Proposals related to drug pricing reform.

Literal federal measure citations: S 43, S 1096, HR 1843, S 1095, S 1097

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.